Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 5/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | LOX | P28300 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6180715 | 0.86 | FFAR1 (0.41) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL18097560 | 0.84 | FFAR1 (0.34) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL4705809 | 0.82 | GABRA1 (0.35) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL1476652 | 0.81 | IKBKB (0.37) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL1477690 | 0.80 | GRM5 (0.43) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL1477497 | 0.79 | SETDB1 (0.43) | — | |
| SCHEMBL3837338 | 0.79 | ALDH1A1 (0.38) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL13620854 | 0.79 | GABRA1 (0.36) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL20455776 | 0.79 | POLB (0.42) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL2793728 | 0.77 | MPO (0.37) | FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023240253-A2 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| EP-1507530-B1 | DIAMINOTHIAZOLES AND USE THEREOF AS CDK4 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2005-11-02 | — | — | EP | disclosed |
| EP-1507530-A1 | DIAMINOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-23 | — | — | EP | disclosed |
| US-6818663-B2 | AS INHIBITORS OF CYCLIN-DEPENDENT KINASE 4 (CDK4); ANTIPROLIFERATIVE AGENTS; FOR THERAPY OF CANCER, TUMORS | HOFFMANN-LA ROCHES | 2004-11-16 | — | — | US | disclosed |
| US-20040006058-A1 | DIAMINOTHIAZOLES | CHU XIN-JIE (US) | 2004-01-08 | — | — | US | disclosed |
| WO-2003097048-A1 | DIAMINOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006058-A1 | DIAMINOTHIAZOLES | CDK4, CDK1, CDK2 | GABRA1 4651/4885GABRA5 4638/4885GABRG2 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.